6-Mercaptopurine and Macrophage Activation Syndrome Case Report and Review of the Literature.
J Pharm Pract
; 36(4): 1015-1019, 2023 Aug.
Article
in En
| MEDLINE
| ID: mdl-35341387
ABSTRACT
Macrophage activation syndrome is a life-threatening syndrome of uncontrolled immune activation with variable clinical presentation making early diagnosis difficult. It is often manifested by the development of multi-organ failure due to systemic inflammatory response. Patients with ulcerative colitis (UC) on purine antimetabolites are at high risk for severe myelosuppression due to the mechanism of thiopurine toxicity which potentially contributes to the development of macrophage activation syndrome. We present a case of a 39-year-old woman with a 2-year history of UC previously treated with 6-mercaptopurine (6-MP) and recent COVID-19 infection, who was admitted to our emergency department for C. difficile infection and subsequently developed macrophage activation syndrome. This case report also raises the question of whether abrupt discontinuation of 6-MP may have contributed to the worsening of the patient's symptoms of underlying hemophagocytic lymphohistiocytosis (HLH) and her rapid deterioration. Both macrophage activation syndrome and COVID-19 infection can produce a large number of pro-inflammatory cytokines termed "cytokine storm," but a pro-inflammatory cytokine panel breakdown helps to differentiate between the two. Our case report emphasizes the importance of close monitoring of patients on purine antimetabolite therapy who present with signs and symptoms of systemic toxicity.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Clostridioides difficile
/
Lymphohistiocytosis, Hemophagocytic
/
Macrophage Activation Syndrome
/
COVID-19
Type of study:
Screening_studies
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
J Pharm Pract
Journal subject:
FARMACIA
Year:
2023
Document type:
Article
Affiliation country: